Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans.
about
Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathwaysA New Perspective on Delusional States - Evidence for Claustrum Involvement.Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disordersNaltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in HumansSalvinorin A administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in pigletsNeuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin AMetabolic changes in the rodent brain after acute administration of salvinorin A.Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brainThe discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors.Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A.Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism.Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.Salvinorin A decreases mortality and improves neurological outcome in a neonatal mouse hypoxia modelFrom divination to madness: features of acute intoxication with Salvia useRepeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.A single injection of a novel κ opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats.Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.Salvinorin A produces cerebrovasodilation through activation of nitric oxide synthase, κ receptor, and adenosine triphosphate-sensitive potassium channel.Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET.Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluidEvaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence.Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuseThe 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats.Salvia divinorum: from Mazatec medicinal and hallucinogenic plant to emerging recreational drug.Kappa Opioid Receptor Agonist and Brain Ischemia.Influence of age on Salvia divinorum use: results of an Internet survey.Salvia divinorum: An overview of the usage, misuse, and addiction processes.Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors.The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and β-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects.The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran Salvinorin B in mice.Analysis of the smoke of cigarettes containing Salvia divinorum.Salvinorin A reduces neuropathic nociception in the insular cortex of the rat.
P2860
Q24643003-29B5A2CE-127A-460F-AC7F-3474C5CA2421Q26776159-1ED658F0-0E24-4453-87FE-5168C6B3AC83Q26781580-3E55B210-7BDB-41EA-876A-67DB7904CBCBQ27300685-9F96E6CA-6DC7-4E65-BB36-71079B9E4294Q28481482-2D8DA9B5-5B2A-42EA-A19E-C9F8B099A44FQ30467220-2759739C-30DA-4348-AF54-04553AB43FEDQ30490227-47C38A7E-A107-4E97-842D-BA94CAFFA45EQ33556502-1F584A53-09E5-42EC-8374-8CC49F7DB7D6Q33835281-B55A97F3-2413-4676-9F70-37A5FE947840Q33918201-0E4C1751-500E-4209-BB97-E2BF96CE397FQ34083438-A6C85587-4860-4A7B-8F04-735D61CCB4B9Q34302349-0A2A258C-DC5D-494B-9C95-79D760D0CADCQ34401390-4E22334E-5E52-4FE3-B3B3-F9061F8611F9Q34820974-04116D70-3B05-4E54-97A9-147A8FDB8659Q34929007-9AFFF723-8E12-4C5E-9BF7-83DE84EC605CQ35269480-0C327A33-E6ED-4626-8135-2B43B1002495Q35837572-3C252EBA-E312-4507-96C3-9E8BE1AACDD6Q35996706-96A36BAD-452F-4482-8732-B84DCCF7B416Q36069379-D7F4CE74-CB86-4109-84AD-1712EF8EFC56Q36894509-9DE1D49A-8622-4DFD-95CA-8725761C2D84Q37192749-486902BD-15EE-410D-91A8-4FBB9EF6F587Q37286215-6F5D6F67-77E2-4A0E-B623-627FCAFAD206Q37349384-ACFD523A-3041-4648-A78A-072F0BFDD761Q37355904-77EC2357-4800-4C4B-BAAA-FF3A09E5341AQ37507887-D2E8CBB2-AA2B-4926-AAA9-4CA921004A04Q38116484-31FFD5A5-F9B4-4CD7-B99C-494F63AF49E9Q38312641-0B431BCE-EEEB-4E55-ADFC-8A2DD94BBB4CQ38550198-354622A6-EF7E-409E-B573-6FBCD9A0A272Q38652778-C89B194D-824E-4141-8250-A101F609A46FQ44343638-A0CA2B1A-04F7-4D55-840D-CAF5309E56C1Q47878237-41C3610B-D371-4C48-BF53-B4426978B3EBQ47977698-869A203C-1CDF-469C-BADD-3826BFD76E97Q48727079-5B7D99D6-3D2A-45E8-9EA9-50BFD2A94D84Q49629222-4A7D663C-2588-499C-830F-241CF8A91803
P2860
Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Pharmacokinetics of the potent ...... duration of effects in humans.
@ast
Pharmacokinetics of the potent ...... duration of effects in humans.
@en
type
label
Pharmacokinetics of the potent ...... duration of effects in humans.
@ast
Pharmacokinetics of the potent ...... duration of effects in humans.
@en
prefLabel
Pharmacokinetics of the potent ...... duration of effects in humans.
@ast
Pharmacokinetics of the potent ...... duration of effects in humans.
@en
P2093
P2860
P1433
P1476
Pharmacokinetics of the potent ...... duration of effects in humans
@en
P2093
Colleen Shea
Joanna S Fowler
Pauline Carter
Wynne Schiffer
P2860
P304
P356
10.1016/J.NEUROIMAGE.2008.03.003
P407
P577
2008-03-15T00:00:00Z